John David Dignam
John David Dignam, Ph.D., is a Professor Emeritus in the Department of Cell and Cancer Biology with a research focus on nucleic acid enzymology, nucleic acid protein interaction, and the development of modified human albumin for the treatment of shock. His studies include investigating aminoacyl tRNA synthetases, the adenoassociated virus 2 as a gene therapy vector, and the development of polyethylene glycol-modified albumin for hypovolemia treatment. With a background in Biochemistry and Microbiology, Dignam has held various academic appointments and has contributed to several publications in the field. He is also a member of the mentoring faculty for the Biomedical Sciences Graduate Program in the Cell and Cancer Biology track at the University of Toledo.